Indian Drugmakers
-
{
- All
- News
-
Five Indian Drugmakers To Jointly Start Trial Of Merck & Co's Covid Drug
Fivegeneric drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in the country.
-
Merck Taps 5 Indian Drugmakers To Expand Covid Drug Production
Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.
-
India’s Pharma Market Grows At Slowest Pace In Five Years
The year-on-year growth in Indian pharma market stood at 7.9 percent in Q1, the lowest since the quarter ended June 2014.
-
Is China The New Frontier For Indian Generics?
China’s new rules allow pharma companies to file for drugs approved by the U.S. FDA.
-
Lupin Falls After U.S. FDA Classifies Pithampur Unit For Official Action
The company said one of its units in Pithampur was classified as “official action indicated” after an inspection by the U.S. FDA.
-
U.S. Drug Regulator’s Inspections In India Spike
U.S. FDA inspections in India jumped 24 percent over a year earlier, says Bank of America Merrill Lynch.
-
Is It Time For Indian Drugmakers To Look Beyond Generics?
Indian drugmakers are looking to focus on this theme in the future.
-
Sun Pharma Bets On New Products To Boost US Skincare Products Growth
India's largest drugmaker Sun Pharmaceutical Industries is banking on the launch of newer and more complex products to offset rising competition in its lucrative U.S. dermatology business, its U.S. chief said.
-
Dr Reddy's, Glenmark See US Sales Hit by Delay in New Approvals
India's $15 billion pharmaceutical industry, which has been hit by a spate of regulatory sanctions in the past year due to concerns about production processes, supplies about 40 per cent of generic and over-the-counter drugs to the United States.
.jpg?downsize=260:146 "India’s Pharma Market Grows At Slowest Pace In Five Years")
-
Five Indian Drugmakers To Jointly Start Trial Of Merck & Co's Covid Drug
Fivegeneric drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in the country.
-
Merck Taps 5 Indian Drugmakers To Expand Covid Drug Production
Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.
-
India’s Pharma Market Grows At Slowest Pace In Five Years
The year-on-year growth in Indian pharma market stood at 7.9 percent in Q1, the lowest since the quarter ended June 2014.
-
Is China The New Frontier For Indian Generics?
China’s new rules allow pharma companies to file for drugs approved by the U.S. FDA.
-
Lupin Falls After U.S. FDA Classifies Pithampur Unit For Official Action
The company said one of its units in Pithampur was classified as “official action indicated” after an inspection by the U.S. FDA.
-
U.S. Drug Regulator’s Inspections In India Spike
U.S. FDA inspections in India jumped 24 percent over a year earlier, says Bank of America Merrill Lynch.
-
Is It Time For Indian Drugmakers To Look Beyond Generics?
Indian drugmakers are looking to focus on this theme in the future.
-
Sun Pharma Bets On New Products To Boost US Skincare Products Growth
India's largest drugmaker Sun Pharmaceutical Industries is banking on the launch of newer and more complex products to offset rising competition in its lucrative U.S. dermatology business, its U.S. chief said.
-
Dr Reddy's, Glenmark See US Sales Hit by Delay in New Approvals
India's $15 billion pharmaceutical industry, which has been hit by a spate of regulatory sanctions in the past year due to concerns about production processes, supplies about 40 per cent of generic and over-the-counter drugs to the United States.
